- Home
- APLM vs BFRI Comparison
APLM vs BFRI Comparison
Compare APLM & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- BFRI
- Stock Information
- Founded
- APLM 2016
- BFRI 1997
- Country
- APLM United States
- BFRI United States
- Employees
- APLM N/A
- BFRI N/A
- Industry
- APLM Blank Checks
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- BFRI Health Care
- Exchange
- APLM Nasdaq
- BFRI Nasdaq
- Market Cap
- APLM 7.7M
- BFRI 7.5M
- IPO Year
- APLM N/A
- BFRI 2021
- Fundamental
- Price
- APLM $6.56
- BFRI $0.81
- Analyst Decision
- APLM Strong Buy
- BFRI Strong Buy
- Analyst Count
- APLM 1
- BFRI 1
- Target Price
- APLM $200.00
- BFRI $7.00
- AVG Volume (30 Days)
- APLM 57.9K
- BFRI 82.4K
- Earning Date
- APLM 04-03-2025
- BFRI 05-14-2025
- Dividend Yield
- APLM N/A
- BFRI N/A
- EPS Growth
- APLM N/A
- BFRI N/A
- EPS
- APLM N/A
- BFRI N/A
- Revenue
- APLM $198,000.00
- BFRI $37,321,000.00
- Revenue This Year
- APLM $415.15
- BFRI $18.57
- Revenue Next Year
- APLM N/A
- BFRI $20.17
- P/E Ratio
- APLM N/A
- BFRI N/A
- Revenue Growth
- APLM N/A
- BFRI 9.54
- 52 Week Low
- APLM $4.71
- BFRI $0.65
- 52 Week High
- APLM $49.00
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- APLM 50.05
- BFRI 46.56
- Support Level
- APLM $5.41
- BFRI $0.76
- Resistance Level
- APLM $6.19
- BFRI $0.87
- Average True Range (ATR)
- APLM 0.76
- BFRI 0.07
- MACD
- APLM 0.10
- BFRI 0.01
- Stochastic Oscillator
- APLM 86.05
- BFRI 71.99
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.